Drug Profile
KH 903
Alternative Names: KH903Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Chengdu Kanghong Pharmaceutical
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in China (IV)
- 23 Sep 2020 KH 903 is still in clinical development in China (Chengdu Kanghong Biological Science & Technology website, September 2020)
- 23 Sep 2020 KH 903 is available for licensing as of 23 Sep 2020. https://en.cnkh.com/innovation.html